Description
ADCC-Enhanced anti-EPHA10 (A1) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced EPHA10 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
EPH receptor A10
Background
Ephrin receptors, the largest subfamily of receptor tyrosine kinases (RTKs), and their ephrin ligands are important mediators of cell-cell communication regulating cell attachment, shape, and mobility in neuronal and epithelial cells (Aasheim et al., 2005 ). See MIM 179610 for additional background on Eph receptors and ephrins.
Alternative Names
EPHA10; EPH receptor A10; ephrin type-A receptor 10; EphA10s protein
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with EPHA10 include Craniofrontonasal Syndrome and Persistent Hyperplastic Primary Vitreous.
Related Pathways
Its related pathways are EPHA forward signaling and Developmental Biology.
Function
Receptor for members of the ephrin-A family. Binds to EFNA3, EFNA4 and EFNA5.
Post-translational modifications
1.Glycosylation at Asn311 and Asn486 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
The monoclonal antibody specifically bind to the Ephrin type-A receptor 10 with high affinity, used for treating various cancers, including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, uterine cancer and pancreatic cancer.
Antibody Indication
Cancer
